Thursday, 20 September 2018
Latest news
Main » Make a note of Analyst's Recommendations: Abbott Laboratories (ABT)

Make a note of Analyst's Recommendations: Abbott Laboratories (ABT)

12 October 2017

The stock increased 0.99% or $0.31 during the last trading session, reaching $31.75. About 6.87 million shares traded or 17.44% up from the average.

On Wednesday, Shares of Abbott Laboratories (NYSE: ABT) expressed a change of -1.73% and closed its trade at $54.44. It has underperformed by 0.80% the S&P500. State of New Jersey Common Pension Fund D owned 0.05% of Abbott Laboratories worth $44,957,000 as of its most recent filing with the Securities and Exchange Commission (SEC). With 4.91 million shares average volume, it will take short sellers 3 days to cover their ABT's short positions. LLC now owns 268,200 shares of the healthcare product maker's stock worth $13,037,000 after buying an additional 5,950 shares during the last quarter. It is down 89.43% since October 11, 2016 and is uptrending. It has underperformed by 16.70% the S&P500. Maxim Group maintained it with "Buy" rating and $59 target in Thursday, October 27 report. Therefore 100% are positive. Rockwell Collins had 65 analyst reports since July 28, 2015 according to SRatingsIntel. Credit Suisse maintained the shares of GE in report on Wednesday, April 12 with "Buy" rating. BMO Capital Markets maintained it with "Hold" rating and $5300 target in Thursday, July 20 report. The firm earned "Buy" rating on Sunday, October 8 by RBC Capital Markets. The rating was maintained by Jefferies on Monday, July 24 with "Hold". The stock has "Hold" rating by Cowen & Co on Wednesday, July 26.

Investors of record on Friday, October 13th will be paid a dividend of $0.265 per share. Its down 0.03, from 0.82 in 2017Q1. Huntington Bank invested in 492,051 shares. 63 funds opened positions while 129 raised stakes. The healthcare product maker reported $0.62 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.60 by $0.02. Institutional investors own 71.50% of the company's stock. Us Bankshares De reported 13,253 shares. Coho Prns Ltd reported 0.02% in General Electric Company (NYSE:GE). Roanoke Asset Management Corp Ny owns 105,283 shares or 0.12% of their United States portfolio. Rhumbline Advisers, a Massachusetts-based fund reported 56,264 shares. Crawford Investment Counsel reported 0.04% stake. (NYSE:AME). Geode Mngmt Limited Liability Com has 0.05% invested in AMETEK, Inc. Pure Fin Advsrs Inc holds 0.15% or 11,315 shares in its portfolio. Cs Mckee Lp reported 1.62% stake. On average, equities research analysts predict that Abbott Laboratories will post $2.49 earnings per share for the current fiscal year. McQueen Ball & Associates Inc. increased its holdings in shares of Abbott Laboratories by 2.8% in the 3rd quarter. They expect $0.65 EPS, up 10.17% or $0.06 from last year's $0.59 per share. GE's profit will be $4.33B for 11.54 P/E if the $0.50 EPS becomes a reality. After having $3.15 EPS previously, Northrop Grumman Corporation's analysts see -6.98% EPS growth. Shares for $53,082 were sold by IGDALOFF BARRY on Thursday, June 1.

Investors sentiment increased to 2.72 in 2017 Q2.

Abbott Laboratories value Change from Open was at -1.30% with a Gap of -0.34%. It worsened, as 69 investors sold Abbott Laboratories shares while 545 reduced holdings.

Abbott Laboratories (ABT) now has a Return on Assets (ROA) value of 2 Percent. Finally, Frontier Investment Mgmt Co. grew its position in Abbott Laboratories by 18.8% in the 2nd quarter. Torch Wealth Management Ltd Llc invested in 1% or 29,733 shares. (NYSE:COL). Tower Bridge holds 0% or 11,080 shares. San Francisco Sentry Investment (Ca) accumulated 0.16% or 9,252 shares. Millennium Mngmt Ltd Limited Liability Company holds 0.04% or 391,284 shares. Stephens Ar has invested 0.32% of its portfolio in Abbott Laboratories (NYSE:ABT).

Major storm causes chaos in Durban, South Africa
A container ship blocks the harbour mouth in Durban , South Africa, October 10, 2017 in this still image obtained from a social media video.

Among 24 analysts covering Abbott Laboratories (NYSE:ABT), 14 have Buy rating, 0 Sell and 10 Hold. Stewart Patten Com Lc accumulated 306,771 shares. 196.23 million shares or 3.91% less from 204.21 million shares in 2017Q1 were reported.

Abbott Laboratories (ABT) has scheduled its 3Q17 earnings release for October 18, 2017. Hutchin Hill Limited Partnership holds 0.04% or 11,500 shares in its portfolio. Teachers Insurance And Annuity Association Of America reported 0.46% stake. NOC's profit would be $513.66 million giving it 25.19 P/E if the $2.93 EPS is correct. The short interest to Abbott Labs's float is 0.94%.

Since June 15, 2017, it had 0 buys, and 1 insider sale for $26,482 activity.

In related news, insider Brian J. Blaser sold 15,000 shares of the firm's stock in a transaction that occurred on Thursday, July 27th. Therefore 58% are positive. Royal Bank Of Canada reissued a "buy" rating and set a $55.00 price objective on shares of Abbott Laboratories in a report on Tuesday, October 3rd. The Lower end of the earnings estimate is $0.71, while the higher end of the earnings estimate is $0.77. The firm presently has a $61.00 target price on the healthcare product maker's stock. BMO Capital Markets maintained Abbott Laboratories (NYSE:ABT) on Thursday, July 20 with "Hold" rating. The firm has "Neutral" rating given on Tuesday, September 22 by UBS. The firm has "Buy" rating given on Saturday, August 29 by BTIG Research. The stock has "Buy" rating by Argus Research on Friday, July 21. Stifel Nicolaus maintained the stock with "Buy" rating in Friday, October 6 report. The rating was maintained by Northland Capital on Friday, August 12 with "Corporate".

The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Make a note of Analyst's Recommendations: Abbott Laboratories (ABT)